- Home
- Media Center
- Press releases
- Medical technologies
Medical technologies
Johnson & Johnson Medical Announces Strategic Partnership With Aussie Startup Navbit To Bring Smartphone-Inspired Tech To Hip Replacement Surgery
· Hip dislocation post hip replacement surgery remains one of the most common causes of revision surgery[i] · Research shows half of acetabular cup implants are unable to achieve their target orientation[ii] due to surgical placement, which can contribute to the risk of hip dislocation,[iii] hip joint wearing out and discomfort[iv] · Johnson & Johnson Medical has entered into an agreement with Navbit to launch Navbit Sprint in Australia - a new navigation system utilising smart sensor technology to assist surgeons in aligning the acetabular cup
Long-Term ERLEADA® (apalutamide) Patient-Reported Outcomes Data in Metastatic Castration-Sensitive Prostate Cancer Demonstrate Maintenance of Health-Related Quality of Life for Patients
Results at ASCO from Phase 3 TITAN study final analysis confirm survival benefit achieved with the addition of ERLEADA® to androgen deprivation therapy without significant side effect burden
RYBREVANTTM (amivantamab-vmjw) Receives FDA Approval as the First Targeted Treatment for Patients with Non-Small Cell Lung Cancer with EGFR Exon 20 Insertion Mutations
RYBREVANTTM is the first fully-human, bispecific antibody approved in lung cancer Simultaneous FDA approval of a companion diagnostic aids in the identification of exon 20 insertion mutations
New Amivantamab Data from CHRYSALIS Study Show Robust Clinical Activity and Durable Responses in Patients with Metastatic or Unresectable Non-Small Cell Lung Cancer and EGFR Exon 20 Insertion Mutations
Data presented have been submitted to U.S. and EU regulatory agencies and represent an important step towards addressing the high unmet need in this patient population
Updated Results from the Phase 1 Study of the BCMAxCD3 Bispecific Teclistamab Show Preliminary Efficacy in Patients with Heavily Pretreated Relapsed or Refractory Multiple Myeloma
First-reported results for the subcutaneous formulation and updated results for the intravenous formulation presented at ASH 2020
Early, Deep, Durable Responses of Ciltacabtagene Autoleucel (cilta-cel) Observed in Phase 1b/2 CARTITUDE-1 Study Show Potential of BCMA CAR-T in Treatment of Heavily Pretreated Patients with Multiple Myeloma
Combined results from Phase 1b/2 CARTITUDE-1 study presented at ASH 2020 show 97 percent overall response rate at median follow-up of 12.4 months
ERLEADA® (apalutamide) Significantly Improved Overall Survival in Patients with Non-Metastatic Castration-Resistant Prostate Cancer
Final analysis of the Phase 3 SPARTAN study presented during ASCO Virtual Scientific Program suggests 14-month improvement in median overall survival